Neuralink pivots to speech BCI clinical trials

Neuralink , the brain-computer interface (BCI) company founded by Elon Musk, has begun clinical trials aimed at restoring speech, starting in May 2026. The move signals a shift away from the company’s earlier emphasis on motor-focused BCIs, which were designed to let users control a computer cursor using neural activity linked to movement.

The speech program is being tested at Cleveland Clinic Abu Dhabi in the United Arab Emirates, according to the trial details described in the source material. A similar speech-restoration trial was also launched in the United States in October 2026, expanding the company’s clinical footprint beyond the Middle East.

This change in direction comes as other groups working on speech-focused BCIs have reported rapid progress in turning brain signals into spoken output. Speech BCIs aim to decode neural patterns tied to speech formation, rather than signals associated with limb movement. The source material points to a 2019 study in which a speech BCI predicted intended words, and to a later milestone in 2024 when an ALS patient reportedly reached 97% accuracy in natural speech using such a device.

Neuralink’s earlier public demonstrations centered on motor decoding. One example cited is a November 2025 demonstration involving patient Brad Smith, who controlled a cursor by thinking about arm movements. That approach reflects the company’s initial focus: translating neural activity related to intended motion into digital commands.

While the applications differ, the source material describes a shared neuroscience foundation across motor and speech BCIs. Both rely on detecting electrical signals from neurons connected to muscle movements—whether those movements involve a finger or the tongue. In practice, the distinction is the target: motor BCIs map signals tied to limb actions, while speech BCIs interpret signals associated with producing speech.

Within the broader BCI community, speech systems have been portrayed as advancing at an unusually fast pace. The source material states that speech BCIs have reached milestones comparable to two-decade-old motor BCI technology within five years, underscoring why companies may prioritize communication-focused use cases.

Neuralink’s speech-restoration trials position the company more directly alongside that trajectory, with an emphasis on patients who have communication impairments. The source material frames the strategic adjustment as an effort to pursue a more immediate and impactful application, though clinical outcomes from Neuralink’s new trials have not been provided in the information available.